Biosergen
Trondheim · Founded 2004
About Biosergen
Biosergen develops variants of nystatin with improved properties. Its pipeline products include S44HP, an antibiotic that is more potent than nystatin against several fungal pathogens; and nystatin analogues produced through manipulation of the nystatin biosynthetic genes.
Company Facts
- Founded: 2004
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $4.1M
- Funding stage: IPO
- Last round: Post-IPO Equity (Nov 2024)
- Ticker: fra:8N1
- Website: https://www.biosergen.net
Industries & Categories
Biotechnology, Pharmaceutical
Canonical: https://fsome.com/organization/biosergen-149095 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.